{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:28:38Z","timestamp":1791646118322,"version":"4.3.4"},"reference-count":199,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P3-067"],"award-info":[{"award-number":["P3-067"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The poor prognosis for high-grade serous ovarian cancer (HGSOC), the dominant subtype of ovarian cancer, reflects its aggressive nature, late diagnosis, and the highest mortality rate among all gynaecologic cancers. Apart from late diagnosis, the main reason for the poor prognosis and its unsuccessful treatment is primarily the emergence of chemoresistance to carboplatin. Although there is a good response to primary treatment, the disease recurs in 80% of cases, at which point it is largely resistant to carboplatin. The introduction of novel targeted therapies in the second decade of the 21st century has begun to transform the treatment of HGSOC, although their impact on overall survival remains unsatisfactory. Targeting the specific pathways known to be abnormally activated in HGSOC is especially difficult due to the molecular diversity of its subtypes. Moreover, a range of molecular changes are associated with acquired chemoresistance, e.g., reversion of BRCA1 and BRCA2 germline alleles. In this review, we examine the advantages and disadvantages of approved targeted therapies, including bevacizumab, PARP inhibitors (PARPis), and treatments targeting cells with neurotrophic tyrosine receptor kinase (NTRK), B-rapidly accelerated fibrosarcoma (BRAF), and rearranged during transfection (RET) gene alterations, as well as antibody\u2013drug conjugates. Additionally, we explore promising new targets under investigation in ongoing clinical trials, such as immune checkpoint inhibitors, anti-angiogenic agents, phosphatidylinositol-3-kinase (PI3K) inhibitors, Wee1 kinase inhibitors, and ataxia telangiectasia and Rad3-related protein (ATR) inhibitors for platinum-resistant disease. Despite the development of new targeted therapies, carboplatin remains the fundamental medicine in HGSOC therapy. The correct choice of treatment strategy for better survival of patients with advanced HGSOC should therefore include a prediction of patients\u2019 risks of developing chemoresistance to platinum-based chemotherapy. Moreover, effective targeted therapy requires the selection of patients who are likely to derive clinical benefit while minimizing potential adverse effects, underscoring the essence of precision medicine.<\/jats:p>","DOI":"10.3390\/ijms26062545","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:31:42Z","timestamp":1741764702000},"page":"2545","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Precision Medicine in High-Grade Serous Ovarian Cancer: Targeted Therapies and the Challenge of Chemoresistance"],"prefix":"10.3390","volume":"26","author":[{"given":"Sara","family":"Polaj\u017eer","sequence":"first","affiliation":[{"name":"Institute of Pharmacology and Experimental Toxicology, Faculty of Medicine, University of Ljubljana, Korytkova 2, SI-1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"\u010cerne","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology and Experimental Toxicology, Faculty of Medicine, University of Ljubljana, Korytkova 2, SI-1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.annonc.2021.12.007","article-title":"European cancer mortality predictions for the year 2022 with focus on ovarian cancer","volume":"33","author":"Dalmartello","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_2","unstructured":"GLOBOCAN (2025, February 19). Global Cancer Observatory. Cancer Today. Available online: https:\/\/gco.iarc.fr\/today\/en\/dataviz\/tables?mode=population&cancers=25&types=1."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Lukanovi\u0107, D., Herzog, M., Kobal, B., and \u010cerne, K. (2020). The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer. Biomed. Pharmacother., 129.","DOI":"10.1016\/j.biopha.2020.110401"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3892\/or.2022.8293","article-title":"Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer (Review)","volume":"47","author":"Mai","year":"2022","journal-title":"Oncol. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ygyno.2022.01.015","article-title":"Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer","volume":"164","author":"Colombo","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/IJWH.S197604","article-title":"Ovarian cancer in the world: Epidemiology and risk factors","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Int. J. Women\u2019s Health"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Huang, J., Chan, W.C., Ngai, C.H., Lok, V., Zhang, L., Lucero-Prisno, D.E., Xu, W., Zheng, Z.J., Elcarte, E., and Withers, M. (2022). Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study. Cancers, 14.","DOI":"10.3390\/cancers14092230"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1001\/jamaoncol.2015.5941","article-title":"BRCA1 and BRCA2 mutation testing in young women with breast cancer","volume":"2","author":"Rosenberg","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1200\/JCO.2005.01.016","article-title":"What is Targeted Therapy?","volume":"23","author":"Sledge","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Lisio, M.A., Fu, L., Goyeneche, A., Gao, Z.H., and Telleria, C. (2019). High-grade serous ovarian cancer: Basic sciences, clinical and therapeutic standpoints. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20040952"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3390\/reprodmed3020011","article-title":"Ovarian Cancer: Treatment and Resistance to Pharmacotherapy","volume":"3","author":"Kobal","year":"2022","journal-title":"Reprod. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","article-title":"Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome","volume":"14","author":"Tothill","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.annonc.2021.04.023","article-title":"PARP inhibitors and newly second primary malignancies in cancer patients: A systematic review and safety meta-analysis of placebo randomized controlled trials","volume":"32","author":"Morice","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_14","unstructured":"Brunton, L.L., Hilal-Dandan, R., and Knollmann, B.C. (2017). Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics, McGraw-Hill Education. [13th ed.]."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO\u2013ESMO\u2013ESP consensus conference recommendations on ovarian cancer: Pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_16","unstructured":"National Comprehensive Cancer Network (2024, May 08). NCCN Guidlines. Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer (Version 1.2024). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf."},{"key":"ref_17","unstructured":"EMA. European Medicines Agency (2025, February 18). Avastin: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/avastin-epar-product-information_en.pdf."},{"key":"ref_18","unstructured":"FDA. Food and Drug Administration (2024, September 05). FDA Approves Olaparib Plus Bevacizumab as Maintenance Treatment for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary."},{"key":"ref_19","unstructured":"EMA. European Medicines Agency (2025, February 18). Lynparza: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lynparza-epar-product-information_en.pdf."},{"key":"ref_20","unstructured":"FDA. Food and Drug Administration (2024, September 05). FDA Approves Olaparib Tablets for Maintenance Treatment in Ovarian Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-tablets-maintenance-treatment-ovarian-cancer."},{"key":"ref_21","unstructured":"EMA. European Medicines Agency (2025, February 18). Zejula: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zejula-epar-product-information_en.pdf."},{"key":"ref_22","unstructured":"FDA. Food and Drug Administration (2024, September 05). FDA Approves Maintenance Treatment for Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancers, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-maintenance-treatment-recurrent-epithelial-ovarian-fallopian-tube-or-primary-peritoneal."},{"key":"ref_23","unstructured":"EMA. European Medicines Agency (2025, February 18). Rubraca: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rubraca-epar-product-information_en.pdf."},{"key":"ref_24","unstructured":"FDA. Food and Drug Administration (2024, September 05). FDA Approves Rucaparib for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-rucaparib-maintenance-treatment-recurrent-ovarian-fallopian-tube-or-primary-peritoneal."},{"key":"ref_25","unstructured":"EMA. European Medicines Agency (2025, February 18). Vitrakvi: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vitrakvi-epar-product-information_en.pdf."},{"key":"ref_26","unstructured":"FDA. Food and Drug Administration (2024, April 25). FDA Approves Larotrectinib for Solid Tumors with NTRK Gene Fusions, Available online: https:\/\/www.fda.gov\/drugs\/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions-0."},{"key":"ref_27","unstructured":"EMA. European Medicines Agency (2025, February 18). Rozlytrek: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rozlytrek-epar-product-information_en.pdf."},{"key":"ref_28","unstructured":"FDA. Food and Drug Administration (2024, April 25). FDA Approves Entrectinib for NTRK Solid Tumors and ROS-1 NSCLC, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc."},{"key":"ref_29","unstructured":"EMA. European Medicines Agency (2025, February 18). Retsevmo: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/retsevmo-epar-product-information_en.pdf."},{"key":"ref_30","unstructured":"FDA. Food and Drug Administration (2024, October 30). FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Advanced Solid Tumors, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors."},{"key":"ref_31","unstructured":"FDA. Food and Drug Administration (2024, May 08). FDA Grants Accelerated Approval to Dabrafenib in Combination with Trametinib for Unresectable or Metastatic Solid Tumors with BRAF V600E Mutation, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid."},{"key":"ref_32","unstructured":"EMA. European Medicines Agency (2025, February 18). Elahere: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elahere-epar-product-information_en.pdf."},{"key":"ref_33","unstructured":"FDA. Food and Drug Administration (2025, February 21). FDA Approves Mirvetuximab Soravtansine-gynx for FR\u03b1 Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant-epithelial-ovarian."},{"key":"ref_34","unstructured":"EMA. Europena Medicines Agency (2024, June 24). Lynparza. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lynparza."},{"key":"ref_35","unstructured":"EMA. European Medicines Agency (2024, June 24). Zejula. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zejula."},{"key":"ref_36","unstructured":"EMA. European Medicines Agency (2024, June 24). Rubraca. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rubraca."},{"key":"ref_37","unstructured":"Drugs.com (2024, June 24). Lynparza FDA Approval History. Available online: https:\/\/www.drugs.com\/history\/lynparza.html."},{"key":"ref_38","unstructured":"Drugs.com (2024, June 24). Zejula FDA Approval History. Available online: https:\/\/www.drugs.com\/history\/zejula.html."},{"key":"ref_39","unstructured":"Drugs.com (2024, June 24). Rubraca FDA Approval History. Available online: https:\/\/www.drugs.com\/history\/rubraca.html."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Rose, M., Burgess, J.T., O\u2019Byrne, K., Richard, D.J., and Bolderson, E. (2020). PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.564601"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1615\/CritRevEukaryotGeneExpr.2013006875","article-title":"Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases","volume":"24","author":"Morales","year":"2014","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/bjc.2011.382","article-title":"The role of PARP in DNA repair and its therapeutic exploitation","volume":"105","author":"Javle","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Bound, N.T., Vandenberg, C.J., Kartikasari, A.E.R., Plebanski, M., and Scott, C.L. (2022). Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.886170"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Cordani, N., Bianchi, T., Ammoni, L.C., Cortinovis, D.L., Cazzaniga, M.E., Lissoni, A.A., Landoni, F., and Canova, S. (2023). An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241511890"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"103984","DOI":"10.1016\/j.esmoop.2024.103984","article-title":"Long-term outcomes of PARP inhibitors in ovarian cancer: Survival, adverse events, and post-progression insights","volume":"9","author":"Tuninetti","year":"2024","journal-title":"ESMO Open"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"102650","DOI":"10.1016\/j.ctrv.2023.102650","article-title":"Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?","volume":"21","author":"Incorvaia","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Luo, J., Ou, S., Wei, H., Qin, X., and Jiang, Q. (2022). Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients with Ovarian Cancer: A Systematic Review and Network Meta-Analysis. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.815265"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Valabrega, G., Scotto, G., Tuninetti, V., Pani, A., and Scaglione, F. (2021). Differences in parp inhibitors for the treatment of ovarian cancer: Mechanisms of action, pharmacology, safety, and efficacy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084203"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1158\/0008-5472.CAN-19-0798","article-title":"Phosphatase 1 nuclear targeting subunit, a novel DNA repair partner of PARP1","volume":"79","author":"Murai","year":"2019","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s11523-018-0606-x","article-title":"Olaparib Tablet: A Review in Ovarian Cancer Maintenance Therapy","volume":"13","author":"Heo","year":"2018","journal-title":"Target. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients with Newly Diagnosed Ovarian Cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e390876","DOI":"10.1200\/EDBK_390876","article-title":"Managing Adverse Effects Associated with Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data","volume":"43","author":"Friedlander","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_55","unstructured":"EMA. European Medicines Agency (2024, September 05). Avastin. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/avastin."},{"key":"ref_56","unstructured":"EMA. European Medicines Agency (2024, September 05). Rozlytrek. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rozlytrek."},{"key":"ref_57","unstructured":"FDA. Food and Drug Administration (2024, May 09). FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumors, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-solid-tumors."},{"key":"ref_58","unstructured":"EMA. European Medicines Agency (2024, September 05). Retsevmo. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/retsevmo."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"8159","DOI":"10.3390\/curroncol30090592","article-title":"Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review","volume":"30","author":"Lazurko","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S1470-2045(20)30142-X","article-title":"Bevacizumab and platinum-based combinations for recurrent ovarian cancer: A randomised, open-label, phase 3 trial","volume":"21","author":"Pfisterer","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.21873\/anticanres.15916","article-title":"Adverse Events Associated With Long-term Treatment of Epithelial Ovarian Cancer With Bevacizumab and Chemotherapy","volume":"42","author":"Yokoyama","year":"2022","journal-title":"Anticancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"367","DOI":"10.21037\/atm-23-903","article-title":"Among patients with advanced ovarian carcinoma, who benefits from bevacizumab the most?","volume":"11","author":"Babaier","year":"2023","journal-title":"Ann. Transl. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1245\/s10434-015-4651-8","article-title":"Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study","volume":"22","author":"Petrillo","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1016\/j.ejca.2013.08.002","article-title":"Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer","volume":"49","author":"Gladieff","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.3802\/jgo.2021.32.e31","article-title":"A single-arm phase ii study of olaparib maintenance with pembrolizumab and bevacizumab in brca non-mutated patients with platinum-sensitive recurrent ovarian cancer (Opeb-01)","volume":"32","author":"Lee","year":"2021","journal-title":"J. Gynecol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5476","DOI":"10.1038\/s41467-023-40829-2","article-title":"Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: The multicenter, single-arm phase II study OPEB-01\/APGOT-OV4","volume":"14","author":"Kim","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Wang, Z., Li, J., Guo, J., and Wei, P. (2024). Direct antitumor activity of bevacizumab: An overlooked mechanism?. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1394878"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Newtson, A., Reyes, H., Devor, E.J., Goodheart, M.J., and Bosquet, J.G. (2021). Identification of novel fusion transcripts in high grade serous ovarian cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094791"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13046-020-01557-3","article-title":"Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer","volume":"39","author":"Guan","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ygyno.2024.09.021","article-title":"Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma","volume":"191","author":"Rushton","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"104234","DOI":"10.1016\/j.critrevonc.2023.104234","article-title":"Oncogenic fusions: Targeting NTRK","volume":"194","author":"Hagopian","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/jclinpath-2018-205679","article-title":"Testing algorithm for identification of patients with TRK fusion cancer","volume":"72","author":"Rudzinski","year":"2019","journal-title":"J. Clin. Pathol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1158\/0008-5472.CAN-18-3126","article-title":"Colorectal carcinomas containing hypermethylated MLH1 promoter and wild-type BRAF\/KRAS are enriched for targetable kinase fusions","volume":"79","author":"Cocco","year":"2019","journal-title":"Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.35036","article-title":"Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas","volume":"129","author":"Kummar","year":"2023","journal-title":"Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion\u2013Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Kotnik, E.N., Mullen, M.M., Spies, N.C., Li, T., Inkman, M., Zhang, J., Martins-Rodrigues, F., Hagemann, I.S., McCourt, C.K., and Thaker, P.H. (2023). Genetic characterization of primary and metastatic high-grade serous ovarian cancer tumors reveals distinct features associated with survival. Commun. Biol., 6.","DOI":"10.1038\/s42003-023-05026-3"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/17512433.2019.1661775","article-title":"Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer","volume":"12","author":"Federman","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40265-018-1044-x","article-title":"Larotrectinib: First Global Approval","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.37765\/ajmc.2022.88845","article-title":"Comparative Effectivness of Larotrectinib and Entrectinib for TRK Fusion Cancer","volume":"28","author":"Carlson","year":"2022","journal-title":"Am. J. Manag. Care"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"119986","DOI":"10.1016\/j.ijpharm.2020.119986","article-title":"Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy","volume":"591","author":"Li","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_85","first-page":"418","article-title":"Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients with NTRK Gene Fusion","volume":"11","author":"Dunn","year":"2020","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s40265-019-01177-y","article-title":"Entrectinib: First Global Approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"101911","DOI":"10.1016\/j.ctrv.2019.101911","article-title":"RET fusions in solid tumors","volume":"81","author":"Li","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.19.02551","article-title":"State-of-the-Art Strategies for Targeting RET-Dependent Cancers","volume":"38","author":"Subbiah","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.1158\/1078-0432.CCR-20-1587","article-title":"Progresses toward precision medicine in RET-altered solid tumors","volume":"26","author":"Belli","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s40265-020-01343-7","article-title":"Selpercatinib: First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): A phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1158\/1078-0432.CCR-23-0459","article-title":"FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors","volume":"29","author":"Duke","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"112675","DOI":"10.1016\/j.ejmech.2020.112675","article-title":"Systemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer","volume":"206","author":"Chavda","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.humpath.2012.07.010","article-title":"Detection of the BRAF V600E mutation in serous ovarian tumors: A comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR","volume":"44","author":"Fischer","year":"2013","journal-title":"Hum. Pathol."},{"key":"ref_96","first-page":"e3600","article-title":"BRAF V600E Mutation in Multiple Primary Malignancies: A Hairy Affair","volume":"10","author":"White","year":"2018","journal-title":"Cureus"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1007\/s11030-023-10699-3","article-title":"An updated literature on BRAF inhibitors (2018\u20132023)","volume":"28","author":"Maji","year":"2023","journal-title":"Mol. Divers."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/PO.21.00055","article-title":"Spectrum of BRAF Mutations and Gene Rearrangements in Ovarian Serous Carcinoma","volume":"5","author":"Chui","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41698-022-00341-0","article-title":"BRAF v600E\u2013mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study","volume":"7","author":"Nelson","year":"2023","journal-title":"NPJ Precis. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E Mutations: Results of the NCI-MATCH Trial Subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: Updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40265-023-01834-3","article-title":"Mirvetuximab Soravtansine: First Approval","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Pettinato, M.C. (2021). Introduction to antibody-drug conjugates. Antibodies, 10.","DOI":"10.3390\/antib10040042"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Manzano, A., and Oca\u00f1a, A. (2020). Antibody-drug conjugates: A promising novel therapy for the treatment of ovarian cancer. Cancers, 12.","DOI":"10.3390\/cancers12082223"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-023-01166-0","article-title":"Antibody-Drug Conjugates in Gynecologic Cancers","volume":"25","author":"Anastasio","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Wilson, E.M., Eskander, R.N., and Binder, P.S. (2024). Recent Therapeutic Advances in Gynecologic Oncology: A Review. Cancers, 16.","DOI":"10.3390\/cancers16040770"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/GCO.0000000000000515","article-title":"Antibody-drug conjugates for ovarian cancer: Current clinical development","volume":"31","author":"Stewart","year":"2019","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"11795549231187264","DOI":"10.1177\/11795549231187264","article-title":"Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer","volume":"17","author":"Veneziani","year":"2023","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e38132","DOI":"10.1097\/MD.0000000000038132","article-title":"Mirvetuximab soravtansine: A breakthrough in targeted therapy for platinum-resistant ovarian cancer","volume":"103","author":"Kokori","year":"2024","journal-title":"Medicine"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results From the SORAYA Study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1080\/17576180.2024.2407228","article-title":"Assessment of mirvetuximab soravtansine immunogenicity in patients with folate receptor alpha-positive ovarian cancer","volume":"16","author":"Zhu","year":"2024","journal-title":"Bioanalysis"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ijgc-2024-005401","article-title":"Mirvetuximab soravtansine in folate receptor alpha (FR\u03b1)\u2013high platinum-resistant ovarian cancer: Final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial","volume":"34","author":"Coleman","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ygyno.2024.01.045","article-title":"Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer","volume":"185","author":"Richardson","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: Primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"101450","DOI":"10.1016\/j.gore.2024.101450","article-title":"Targeted therapy in high grade serous ovarian Cancer: A literature review","volume":"54","author":"Dinkins","year":"2024","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/15384047.2020.1868937","article-title":"Ovarian cancer: New strategies and emerging targets for the treatment of patients with advanced disease","volume":"22","author":"Arend","year":"2021","journal-title":"Cancer Biol. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00262-021-02849-z","article-title":"PD-1\/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures","volume":"70","author":"Appleton","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ygyno.2024.05.002","article-title":"A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib","volume":"187","author":"Liu","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1038\/s41416-023-02455-z","article-title":"Frequency of peripheral PD-1+regulatory T cells is associated with treatment responses to PARP inhibitor maintenance in patients with epithelial ovarian cancer","volume":"129","author":"Park","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Maiorano, B.A., Maiorano, M.F.P., Lorusso, D., and Maiello, E. (2021). Ovarian cancer in the era of immune checkpoint inhibitors: State of the art and future perspectives. Cancers, 13.","DOI":"10.20944\/preprints202108.0037.v1"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.intimp.2017.08.017","article-title":"Prognostic value of tumor PD-L1 expression combined with CD8+ tumor infiltrating lymphocytes in high grade serous ovarian cancer","volume":"52","author":"Wang","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41419-023-06389-5","article-title":"Mechanisms of immune checkpoint inhibitors: Insights into the regulation of circular RNAS involved in cancer hallmarks","volume":"15","author":"Meng","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Pfeiffer, P., Qvortrup, C., and Hansen, K.H. (2021). How to select cancer patients for immunotherapy. eBioMedicine, 63.","DOI":"10.1016\/j.ebiom.2020.103184"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"ix77","DOI":"10.1093\/annonc\/mdz426.039","article-title":"ENGOT-ov43\/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA\u2019-nonmutated advanced epithelial ovarian cancer","volume":"30","author":"Fujiwara","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13048-024-01523-z","article-title":"ADC: A deadly killer of platinum resistant ovarian cancer","volume":"17","author":"Cheng","year":"2024","journal-title":"J. Ovarian Res."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Atallah, G.A., Kampan, N.C., Chew, K.T., Mohd Mokhtar, N., Md Zin, R.R., Shafiee, M.N.B., and Abd. Aziz, N.H.B. (2023). Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24031973"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Zhou, L., Wan, Y., Zhang, L., Meng, H., Yuan, L., Zhou, S., Cheng, W., and Jiang, Y. (2024). Beyond monotherapy: An era ushering in combinations of PARP inhibitors with immune checkpoint inhibitors for solid tumors. Biomed. Pharmacother., 175.","DOI":"10.1016\/j.biopha.2024.116733"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-Arm Phases 1 and 2 Trial of Niraparib in Combination with Pembrolizumab in Patients with Recurrent Platinum-Resistant Ovarian Carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/ijgc-2021-002933","article-title":"ATHENA (GOG-3020\/ENGOT-ov45): A randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA\u2013MONO) and rucaparib in combination with nivolumab (ATHENA\u2013COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer","volume":"31","author":"Monk","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"104047","DOI":"10.1016\/j.amsu.2022.104047","article-title":"Jemperli (Dostarlimab-gxly): An unprecedented cancer trial","volume":"79","author":"Ali","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., and Bian, Y. (2023). Immune-related adverse events of immune checkpoint inhibitors: A review. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1167975"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.2217\/fon-2022-0666","article-title":"EPIK-O\/ENGOT-OV61: Alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)","volume":"18","author":"Konstantinopoulos","year":"2022","journal-title":"Future Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S1470-2045(18)30905-7","article-title":"Olaparib and \u03b1-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: A dose-escalation and dose-expansion phase 1b trial","volume":"20","author":"Konstantinopoulos","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Ye, Y., Huang, Z., Zhang, M., Li, J., Zhang, Y., and Lou, C. (2023). Synergistic therapeutic potential of alpelisib in cancers (excluding breast cancer): Preclinical and clinical evidences. Biomed. Pharmacother., 159.","DOI":"10.1016\/j.biopha.2022.114183"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11523-023-00965-7","article-title":"A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors","volume":"18","author":"Bauer","year":"2023","journal-title":"Target Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10637-023-01371-6","article-title":"A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors","volume":"41","author":"Falchook","year":"2023","journal-title":"Investig. New Drugs"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygyno.2023.05.063","article-title":"WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study","volume":"174","author":"Embaby","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1200\/JCO.2016.67.5991","article-title":"Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors","volume":"34","author":"Leijen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","article-title":"Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Lheureux","year":"2021","journal-title":"Lancet"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Roering, P., Siddiqui, A., Heuser, V.D., Potdar, S., Mikkonen, P., Oikkonen, J., Li, Y., Pikkusaari, S., Wennerberg, K., and Hynninen, J. (2022). Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.954430"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1200\/JCO.2016.67.5942","article-title":"Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patientswith tp53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months","volume":"34","author":"Leijen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/1078-0432.CCR-21-0158","article-title":"Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study","volume":"28","author":"Moore","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"107450","DOI":"10.1016\/j.pharmthera.2019.107450","article-title":"Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?","volume":"207","author":"Bradbury","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Biega\u0142a, \u0141., Gajek, A., Szymczak-Pajor, I., Marczak, A., \u015aliwi\u0144ska, A., and Rogalska, A. (2023). Targeted inhibition of the ATR\/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2 MUT ovarian cancer cells. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-50151-y"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","article-title":"Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor\u2013Resistant Homologous Recombination\u2013Deficient Ovarian Cancer","volume":"29","author":"Wethington","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1038\/s41467-021-25904-w","article-title":"A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer","volume":"12","author":"Konstantinopoulos","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1158\/1078-0432.CCR-21-1733","article-title":"Cediranib in Combination with Olaparib in Patients without a Germline BRCA1\/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial","volume":"28","author":"Lee","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","article-title":"Cancer biomarkers: Emerging trends and clinical implications for personalized treatment","volume":"187","author":"Passaro","year":"2024","journal-title":"Cell"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e13323","DOI":"10.1016\/j.heliyon.2023.e13323","article-title":"Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of COVID-19 and other diseases","volume":"9","author":"Bodaghi","year":"2023","journal-title":"Heliyon"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1093\/bioinformatics\/bty357","article-title":"Distinguishing prognostic and predictive biomarkers: An information theoretic approach","volume":"34","author":"Sechidis","year":"2018","journal-title":"Bioinformatics"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"215828","DOI":"10.1016\/j.canlet.2022.215828","article-title":"Predictive biomarkers for personalized medicine in breast cancer","volume":"545","author":"Nahmias","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp. Biol. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ijc.34908","article-title":"Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression","volume":"155","author":"Rob","year":"2024","journal-title":"Int. J. Cancer"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Havasi, A., Cainap, S.S., Havasi, A.T., and Cainap, C. (2023). Ovarian Cancer\u2014Insights into Platinum Resistance and Overcoming It. Medicina, 59.","DOI":"10.3390\/medicina59030544"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Wiedemeyer, W.R., Beach, J.A., and Karlan, B.Y. (2014). Reversing platinum resistance in high-grade serous ovarian carcinoma: Targeting BRCA and the homologous recombination system. Front. Oncol., 4.","DOI":"10.3389\/fonc.2014.00034"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5114\/wo.2021.112037","article-title":"What is new about ovarian malignancies?","volume":"25","author":"Grabska","year":"2021","journal-title":"Wspolczesna Onkol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.semcancer.2021.08.005","article-title":"Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management","volume":"77","author":"Khan","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Al-Moghrabi, N., Al-Showimi, M., Alqahtani, A., Almalik, O., Alhusaini, H., Almalki, G., Saad, A., and Alsunayi, E. (2024). Constitutional BRCA1 and MGMT Methylation Are Significant Risk Factors for Triple-Negative Breast Cancer and High-Grade Serous Ovarian Cancer in Saudi Women. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063108"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Flores-Col\u00f3n, M., Rivera-Serrano, M., Reyes-Burgos, V.G., Rol\u00f3n, J.G., P\u00e9rez-Santiago, J., Marcos-Mart\u00ednez, M.J., Valiyeva, F., and Vivas-Mej\u00eda, P.E. (2024). MicroRNA Expression Profiles in Human Samples and Cell Lines Revealed Nine miRNAs Associated with Cisplatin Resistance in High-Grade Serous Ovarian Cancer. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25073793"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3892\/or.2022.8313","article-title":"Tumor microenvironment manipulates chemoresistance in ovarian cancer (Review)","volume":"47","author":"Zhang","year":"2022","journal-title":"Oncol. Rep."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Ardighieri, L., Missale, F., Bugatti, M., Gatta, L.B., Pezzali, I., Monti, M., Gottardi, S., Zanotti, L., Bignotti, E., and Ravaggi, A. (2021). Infiltration by CXCL10 Secreting Macrophages Is Associated with Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.690201"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e004029","DOI":"10.1136\/jitc-2021-004029","article-title":"CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype","volume":"10","author":"Li","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1038\/onc.2014.296","article-title":"p53 protein aggregation promotes platinum resistance in ovarian cancer","volume":"34","author":"Soteras","year":"2015","journal-title":"Oncogene"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Oturkar, C.C., Gandhi, N., Rao, P., Eng, K.H., Miller, A., Singh, P.K., Zsiros, E., Odunsi, K.O., and Das, G.M. (2022). Estrogen Receptor-beta2 (ER\u03b22)\u2013Mutant p53\u2013FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC). Cancers, 14.","DOI":"10.3390\/cancers14051120"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.annonc.2022.11.003","article-title":"Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: Phase III PAOLA-1\/ENGOT-ov25 trial subgroup exploratory analysis","volume":"34","author":"Rodrigues","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Yubero, A., Barqu\u00edn, A., Est\u00e9vez, P., Pajares, B., S\u00e1nchez, L., Reche, P., Alarc\u00f3n, J., Calzas, J., Gaba, L., and Fuentes, J. (2022). Rucaparib in recurrent ovarian cancer: Real-world experience from the rucaparib early access programme in Spain\u2014A GEICO study. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10191-5"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/ijgc-2022-004079","article-title":"Safety and management of niraparib monotherapy in ovarian cancer clinical trials","volume":"33","author":"Monk","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","article-title":"Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: Post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial","volume":"33","author":"Frenel","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall Survival with Maintenance Olaparib at a 7-Year Follow-Up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1\/GOG 3004 Trial","volume":"41","author":"Disilvestro","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2019.10.023","article-title":"Olaparib as maintenance therapy in patients with BRCA 1\u20132 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome","volume":"156","author":"Cecere","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s11864-022-00938-4","article-title":"Appropriate Selection of PARP Inhibitors in Ovarian Cancer","volume":"23","author":"Smith","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/ijgc-2023-004995","article-title":"Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Lorusso","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Matuszczak, M., Kilja\u0144czyk, A., Marciniak, W., Derkacz, R., Stempa, K., Baszuk, P., Bry\u015bkiewicz, M., Cybulski, C., D\u0119bniak, T., and Gronwald, J. (2024). Antioxidant Properties of Zinc and Copper\u2014Blood Zinc-to Copper-Ratio as a Marker of Cancer Risk BRCA1 Mutation Carriers. Antioxidants, 13.","DOI":"10.3390\/antiox13070841"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Kong, R., and Sun, G. (2023). Targeting copper metabolism: A promising strategy for cancer treatment. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1203447"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Lukanovi\u0107, D., Polaj\u017eer, S., Matja\u0161i\u010d, M., Kobal, B., and \u010cerne, K. (2024). Analysis of ATP7A Expression and Ceruloplasmin Levels as Biomarkers in Patients Undergoing Neoadjuvant Chemotherapy for Advanced High-Grade Serous Ovarian Carcinoma. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251810195"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Kilja\u0144czyk, A., Matuszczak, M., Marciniak, W., Derkacz, R., Stempa, K., Baszuk, P., Bry\u015bkiewicz, M., Lubi\u0144ski, K., Cybulski, C., and D\u0119bniak, T. (2024). Blood Lead Level as Marker of Increased Risk of Ovarian Cancer in BRCA1 Carriers. Nutrients, 16.","DOI":"10.3390\/nu16091370"},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Kluza, M., Paszek, S., Kluza, K., Januszek, S., Potocka, N., Skrzypa, M., Zuchowska, A., Wr\u00f3bel, A., Baszuk, P., and Marciniak, W. (2023). An Assessment of Serum Selenium Concentration in Women with Ovarian Cancer. Nutrients, 15.","DOI":"10.3390\/nu15040850"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Golara, A., Koz\u0142owski, M., Guzik, P., Kwiatkowski, S., and Cymbaluk-P\u0142oska, A. (2023). The Role of Selenium and Manganese in the Formation, Diagnosis and Treatment of Cervical, Endometrial and Ovarian Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310887"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"e174013","DOI":"10.1172\/JCI174013","article-title":"Biology-driven therapy advances in high-grade serous ovarian cancer","volume":"134","author":"Wang","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2217\/cer-2021-0247","article-title":"Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers","volume":"11","author":"Suh","year":"2022","journal-title":"J. Comp. Eff. Res."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.3802\/jgo.2024.35.e104","article-title":"Targeting BRAF pathway in low-grade serous ovarian cancer","volume":"35","author":"Perrone","year":"2024","journal-title":"J. Gynecol. Oncol."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"De Braud, F., Deschler-Baier, B., Morris, J.C., Worden, F., Han, Y., Kiiskinen, U., Jen, M.H., Barker, S.S., Szymczak, S., and Gilligan, A.M. (2024). Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001. Cancers, 16.","DOI":"10.3390\/cancers16010140"},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Mai, J., Wu, L., Yang, L., Sun, T., Liu, X., Yin, R., Jiang, Y., Li, J., and Li, Q. (2023). Therapeutic strategies targeting folate receptor \u03b1 for ovarian cancer. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1254532"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.socscimed.2011.11.026","article-title":"Social determinants of health\u2014A question of social or economic capital? Interaction effects of socioeconomic factors on health outcomes","volume":"74","author":"Ahnquist","year":"2012","journal-title":"Soc. Sci. Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.annonc.2020.09.017","article-title":"Patient selection biomarker strategies for PARP inhibitor therapy","volume":"31","author":"George","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Louren\u00e7\u00e3o, M., Sim\u00f5es Correa Galendi, J., de Campos Reis Galv\u00e3o, H., Antoniazzi, A.P., Grasel, R.S., Carvalho, A.L., Mauad, E.C., de Oliveira, J.H.C., Reis, R.M., and Mandrik, O. (2022). Cost-Effectiveness of BRCA 1\/2 Genetic Test and Preventive Strategies: Using Real-World Data from an Upper-Middle Income Country. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.951310"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s12325-024-02791-3","article-title":"Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy","volume":"41","author":"Rognoni","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2020.08.003","article-title":"Cost-effectiveness analysis comparing \u201cPARP inhibitors-for-all\u201d to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer","volume":"159","author":"Gonzalez","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.12998\/wjcc.v9.i24.6999","article-title":"Cost-effective screening using a two-antibody panel for detecting mismatch repair deficiency in sporadic colorectal cancer","volume":"9","author":"Kim","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"128","DOI":"10.36469\/2022.35329","article-title":"Healthcare Costs and Resource Use Associated with Cervical Intraepithelial Neoplasia and Cervical Conization: A Retrospective Study of German Statutory Health Insurance Claims Data","volume":"9","author":"Stephan","year":"2022","journal-title":"J. Health Econ. Outcomes Res."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/gim.2017.247","article-title":"Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature","volume":"20","author":"Schwarze","year":"2018","journal-title":"Genet. Med."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1097\/CM9.0000000000001120","article-title":"Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer","volume":"133","author":"Li","year":"2020","journal-title":"Chin. Med. J."},{"key":"ref_194","unstructured":"CostHelper (2025, February 19). Health. How Much Does Ovarian Cancer Treatment Cost?. Available online: https:\/\/health.costhelper.com\/ovarian-cancer.html#:~:text=For%20patients%20without%20health%20insurance%2C%20the%20cost%20of,treatment%20with%20surgery%20and%20chemotherapy%20for%20advanced%20cancer."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1097\/AOG.0000000000002317","article-title":"Cost of care for the initial management of ovarian cancer","volume":"130","author":"Bercow","year":"2017","journal-title":"Obstet. Gynecol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ygyno.2020.12.039","article-title":"The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?","volume":"160","author":"Goldsberry","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1016\/j.jval.2024.03.583","article-title":"EE284 Cost-Effectiveness Analysis of Larotrectinib and Entrectinib for Adult Patients with NTRK Gene Fusion-Positive Breast Cancer","volume":"27","author":"Dheer","year":"2024","journal-title":"Value Health"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S1470-2045(20)30139-X","article-title":"Prices and clinical benefit of cancer drugs in the USA and Europe: A cost\u2013benefit analysis","volume":"21","author":"Vokinger","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s11096-024-01800-3","article-title":"Cost-effectiveness analysis of selpercatinib versus chemotherapy and pembrolizumab in the first-line treatment of rearranged during transfection fusion\u2013positive non-small cell lung cancer in the United States","volume":"46","author":"Yi","year":"2024","journal-title":"Int. J. Clin. Pharm."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/6\/2545\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:51:18Z","timestamp":1760028678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/6\/2545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":199,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["ijms26062545"],"URL":"https:\/\/doi.org\/10.3390\/ijms26062545","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]}}}